4/3
05:05 pm
cprx
Why a Clutch of Pharmaceutical and Biotech Stocks Escaped the Market's Swoon on Thursday [Yahoo! Finance]
Medium
Report
Why a Clutch of Pharmaceutical and Biotech Stocks Escaped the Market's Swoon on Thursday [Yahoo! Finance]
4/2
08:32 am
cprx
What Makes Catalyst Pharmaceuticals (CPRX) an Investment Choice? [Yahoo! Finance]
Medium
Report
What Makes Catalyst Pharmaceuticals (CPRX) an Investment Choice? [Yahoo! Finance]
3/24
03:48 am
cprx
Santhera to share latest on commercial rollout of AGAMREE® and future strategic priorities at Capital Markets Day [Yahoo! Finance]
Medium
Report
Santhera to share latest on commercial rollout of AGAMREE® and future strategic priorities at Capital Markets Day [Yahoo! Finance]
3/14
11:07 am
cprx
Is Catalyst Pharmaceuticals, Inc. (CPRX) the Best Healthcare Stock For Long-Term Investment? [Yahoo! Finance]
Low
Report
Is Catalyst Pharmaceuticals, Inc. (CPRX) the Best Healthcare Stock For Long-Term Investment? [Yahoo! Finance]
3/5
06:51 am
cprx
We Think Catalyst Pharmaceuticals' (NASDAQ:CPRX) Robust Earnings Are Conservative [Yahoo! Finance]
Low
Report
We Think Catalyst Pharmaceuticals' (NASDAQ:CPRX) Robust Earnings Are Conservative [Yahoo! Finance]
3/4
08:03 am
cprx
Catalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare Conference
Medium
Report
Catalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare Conference
3/4
02:04 am
cprx
Full Year Trading Update [Yahoo! Finance]
Low
Report
Full Year Trading Update [Yahoo! Finance]
3/3
08:10 am
cprx
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) had its price target raised by analysts at Robert W. Baird from $28.00 to $32.00. They now have an "outperform" rating on the stock.
Medium
Report
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) had its price target raised by analysts at Robert W. Baird from $28.00 to $32.00. They now have an "outperform" rating on the stock.
2/28
11:04 pm
cprx
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Low
Report
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
2/28
07:07 pm
cprx
Catalyst Pharmaceuticals Inc (CPRX) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ... [Yahoo! Finance]
Low
Report
Catalyst Pharmaceuticals Inc (CPRX) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ... [Yahoo! Finance]
2/28
09:31 am
cprx
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
Medium
Report
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
2/28
08:02 am
cprx
Catalyst Pharmaceuticals Full Year 2024 Earnings: Beats Expectations [Yahoo! Finance]
Medium
Report
Catalyst Pharmaceuticals Full Year 2024 Earnings: Beats Expectations [Yahoo! Finance]
2/27
09:51 am
cprx
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) had its "overweight" rating re-affirmed by analysts at Stephens. They now have a $33.00 price target on the stock.
Medium
Report
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) had its "overweight" rating re-affirmed by analysts at Stephens. They now have a $33.00 price target on the stock.
2/27
09:44 am
cprx
Catalyst Pharmaceutical (CPRX) Tops Q4 Earnings and Revenue Estimates [Yahoo! Finance]
Medium
Report
Catalyst Pharmaceutical (CPRX) Tops Q4 Earnings and Revenue Estimates [Yahoo! Finance]
2/27
09:44 am
cprx
Catalyst (CPRX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates [Yahoo! Finance]
Medium
Report
Catalyst (CPRX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates [Yahoo! Finance]
2/26
04:13 pm
cprx
Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Low
Report
Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
2/25
07:07 pm
cprx
Catalyst Pharmaceuticals Inc (CPRX) Q4 2024: Everything You Need To Know Ahead Of Earnings [Yahoo! Finance]
Low
Report
Catalyst Pharmaceuticals Inc (CPRX) Q4 2024: Everything You Need To Know Ahead Of Earnings [Yahoo! Finance]
2/17
07:56 am
cprx
Those who invested in Catalyst Pharmaceuticals (NASDAQ:CPRX) five years ago are up 374% [Yahoo! Finance]
Low
Report
Those who invested in Catalyst Pharmaceuticals (NASDAQ:CPRX) five years ago are up 374% [Yahoo! Finance]
2/12
10:24 am
cprx
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025 [Yahoo! Finance]
Low
Report
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025 [Yahoo! Finance]
2/12
08:03 am
cprx
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025
Low
Report
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025
2/10
01:47 am
cprx
Santhera Announces Chief Financial Officer Transition with Appointment of Catherine Isted [Yahoo! Finance]
Low
Report
Santhera Announces Chief Financial Officer Transition with Appointment of Catherine Isted [Yahoo! Finance]
2/5
06:27 am
cprx
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) was upgraded by analysts at Baird R W to a "strong-buy" rating.
Low
Report
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) was upgraded by analysts at Baird R W to a "strong-buy" rating.
2/4
08:00 am
cprx
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) is now covered by analysts at Robert W. Baird. They set an "outperform" rating and a $28.00 price target on the stock.
Low
Report
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) is now covered by analysts at Robert W. Baird. They set an "outperform" rating and a $28.00 price target on the stock.
1/23
08:03 am
cprx
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2025 List of America's Most Successful Mid-Cap Companies
Low
Report
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2025 List of America's Most Successful Mid-Cap Companies
1/21
08:19 am
cprx
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan
Low
Report
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan